"Promising Results: Pfizer and BioNTech's Flu-COVID Shot Elicits Robust Immune Response in Trial"

Pfizer and BioNTech announced that their flu-COVID vaccine generated a strong immune response against strains of both viruses in an early- to mid-stage trial. The vaccine candidates were compared to a licensed influenza vaccine and the companies' updated COVID-19 vaccine, and the data showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. The companies plan to proceed with a late-stage trial in the coming months, with the potential to simplify immunization practices by addressing two respiratory diseases with a single injection.